AHA/ASA guideline recommendations for prevention of stroke in women menopause and postmenopausal hormonal therapy: Difference between revisions
< AHA
No edit summary |
m (Bot: Adding CME Category::Cardiology) |
||
Line 15: | Line 15: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | |||
{{WH}} | |||
[[CME Category::Cardiology]] | |||
[[Category:Aging-associated diseases]] | [[Category:Aging-associated diseases]] | ||
Line 27: | Line 31: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
Latest revision as of 19:35, 14 March 2016
Stroke Main page | |
Diagnosis | |
---|---|
Treatment | |
Case Studies | |
AHA/ASA guideline recommendations for prevention of stroke in women menopause and postmenopausal hormonal therapy On the Web | |
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke in women menopause and postmenopausal hormonal therapy | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]
2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)[1]
Postmenopausal Hormonal Therapy
Class III (No Benefit) |
"1. HT (CEE with or without medroxyprogesterone) should not be used for primary or secondary prevention of stroke in postmenopausal women. (Level of Evidence: A) " |
"2. Selective estrogen receptor modulators, such as raloxifene, tamoxifen, or tibolone, should not be used for primary prevention of stroke. (Level of Evidence: A) " |
References
- ↑ Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL; et al. (2014). "Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association". Stroke. doi:10.1161/01.str.0000442009.06663.48. PMID 24503673.